Small-molecule APIs are becoming increasingly complex, with new drug modalities requiring more synthetic steps than ever before. Developing your synthetic route has become more time-consuming and resource-intensive, which can delay getting your medicine into the market.
Advanced technologies, such as Lonza’s AI-enabled route scouting tool, high-throughput experimentation (HTE) equipment, and the Design2Optimize™ platform, allow you to optimize your method faster. Learn how these systems operate and how they work together to streamline your development.
Jens Schmidt
Associate Director of Manufacturing, Science, and Technology,
Lonza Advanced Synthesis
Charles Johnson
Senior Director of Commercial Development,
Lonza Advanced Synthesis
Nichola McCann
Senior Principle Scientist of Process Technologies and Innovation,
Lonza Advanced Synthesis
Copyright © 2025 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy